{"id":"voriconazole-high-dose","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Visual disturbances (blurred vision, photopsia)"},{"rate":"10-20","effect":"Hepatotoxicity (elevated transaminases)"},{"rate":"5-10","effect":"Rash"},{"rate":"5-10","effect":"Photosensitivity"},{"rate":"5-10","effect":"Hallucinations"},{"rate":"5-10","effect":"Hypokalemia"},{"rate":"5-10","effect":"Nausea and vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Voriconazole is a triazole antifungal that selectively targets fungal sterol synthesis by inhibiting the enzyme lanosterol 14α-demethylase (CYP51). This prevents the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane. The resulting depletion of ergosterol and accumulation of toxic sterol precursors leads to fungal cell membrane instability and cell death. High-dose regimens are used to achieve adequate tissue penetration, particularly in the central nervous system and for treatment of invasive infections.","oneSentence":"Voriconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:15:52.888Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Invasive aspergillosis"},{"name":"Candidemia and other Candida infections"},{"name":"Esophageal candidiasis"},{"name":"Cryptococcal meningitis"},{"name":"Scedosporium and Fusarium infections"}]},"trialDetails":[{"nctId":"NCT04988555","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)","status":"RECRUITING","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2022-02-28","conditions":"Leukemia, Myeloid, Acute, Leukemia, Lymphocytic, Acute, Multiple Myeloma","enrollment":606},{"nctId":"NCT06928376","phase":"PHASE2","title":"A Multicenter RCT of \"3+7\" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2024-04-18","conditions":"Acute Myeloid Leukemia, First Line Therapy","enrollment":160},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT07044544","phase":"PHASE1","title":"Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-07-17","conditions":"Myeloid Malignancy, Hematologic Malignancy, Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT07215273","phase":"PHASE2","title":"Study of EL219 vs Standard of Care for Early Antifungal Therapy of Suspected Invasive Mould Infections","status":"RECRUITING","sponsor":"Elion Therapeutics, Inc.","startDate":"2026-02","conditions":"Suspected Invasive Mould Infection","enrollment":80},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT06129734","phase":"PHASE1, PHASE2","title":"Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant","status":"RECRUITING","sponsor":"Benjamin Tomlinson","startDate":"2025-07-28","conditions":"Myeloid Malignancy, Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT06926569","phase":"NA","title":"Single High-dose of Liposomal Amphotericin B in Combination With B/F/TAF for HIV/AIDS-associated Talaromycosis","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Public Health Clinical Center","startDate":"2025-05-01","conditions":"HIV/AIDS-associated Talaromycosis","enrollment":116},{"nctId":"NCT06680544","phase":"PHASE2","title":"Role of Oral Voriconazole in the Treatment of Resistant Dermatophyte Infections","status":"NOT_YET_RECRUITING","sponsor":"Sheikh Zayed Medical College","startDate":"2024-11-15","conditions":"Dermatophyte Infection","enrollment":120},{"nctId":"NCT05841771","phase":"PHASE2","title":"Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2023-01-01","conditions":"Hypomethylating Agent, Venetoclax, Myeloid Malignancy","enrollment":78},{"nctId":"NCT05330000","phase":"PHASE1","title":"Comparative Study on Tolerance and Pharmacokinetics of Voriconazole for Injection in Healthy Subjects","status":"COMPLETED","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2020-05-22","conditions":"Healthy Adults","enrollment":48},{"nctId":"NCT04966234","phase":"PHASE2, PHASE3","title":"A New Posaconazole Dosing Regimen for Paediatric Patients With Cystic Fibrosis and Aspergillus Infection","status":"UNKNOWN","sponsor":"Bambino Gesù Hospital and Research Institute","startDate":"2021-04-22","conditions":"Cystic Fibrosis, Aspergillosis","enrollment":135},{"nctId":"NCT01030653","phase":"PHASE4","title":"Pharmacokinetics of Voriconazole in Obese Subjects","status":"COMPLETED","sponsor":"Manjunath Prakash Pai","startDate":"2009-11","conditions":"Healthy","enrollment":10},{"nctId":"NCT00556998","phase":"PHASE2","title":"A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-06","conditions":"Pharmacokinetics","enrollment":26},{"nctId":"NCT01383993","phase":"PHASE2","title":"Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal Infection","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-09","conditions":"Aspergillosis, Aspergilloma","enrollment":21},{"nctId":"NCT00150345","phase":"PHASE3","title":"Immediate vs. Deferred Empirical Antifungal Treatment With Voriconazole In Neutropenic Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-01","conditions":"Possible Fungal Infection","enrollment":147},{"nctId":"NCT01137292","phase":"","title":"Open, Non Comparative Study Of Voriconazole In Slovak Patients With Very High Risk Of Developing An Invasive Fungal Infection","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-04","conditions":"Invasive Fungal Infections","enrollment":177},{"nctId":"NCT00739934","phase":"PHASE2","title":"Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To 11 Years Old Who Are At High Risk For Systemic Fungal Infection","status":"COMPLETED","sponsor":"Pfizer","startDate":"2008-12","conditions":"Candidiasis, Candidemia","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":126,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Vfend"],"phase":"marketed","status":"active","brandName":"Voriconazole high dose","genericName":"Voriconazole high dose","companyName":"Manjunath Prakash Pai","companyId":"manjunath-prakash-pai","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Voriconazole inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Invasive aspergillosis, Candidemia and other Candida infections, Esophageal candidiasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}